Prolia (Denosumab) Compassionate Use and Expanded Access: How to Get It Cheaper

What "Compassionate Use" Actually Means for an Approved Drug Like Prolia

Compassionate use, formally called expanded access under 21 CFR Part 312 Subpart I, is an FDA mechanism that lets patients outside a clinical trial receive an investigational drug. Prolia received full FDA approval for postmenopausal osteoporosis on June 1, 2010, following the FREEDOM trial (N=7,808), which showed a 68% relative reduction in new vertebral fractures at 3 years versus placebo. Because the drug is approved, compassionate use does not apply to its labeled indications.

The FDA's own guidance states: "Expanded access is for patients who have a serious or immediately life-threatening disease or condition and who lack therapeutic alternatives." For patients who simply cannot afford an approved drug, the correct pathway is a patient assistance program, a co-pay card, or a 340B-covered clinic, not a compassionate-use application.

When Expanded Access Could Still Apply for Denosumab

A narrow scenario does exist. Denosumab is being studied for conditions beyond its current approved label, including giant cell tumor of bone in pediatric patients under age 12, certain metabolic bone diseases in skeletally immature patients, and fibrous dysplasia. Patients with those unapproved conditions may pursue FDA expanded access through their treating physician.

To submit an expanded-access request, a physician files FDA Form 3926 (individual patient expanded access IND) and contacts Amgen's Medical Affairs team directly. Amgen's contact for compassionate use inquiries is medinfo@amgen.com. The FDA typically responds to emergency requests within 24 hours and to non-emergency requests within 30 days. FDA expanded access guidance

The FREEDOM Trial and Why Approval Matters for Access

The key FREEDOM study, published in the New England Journal of Medicine in 2009, enrolled 7,808 women aged 60 to 90 with a bone mineral density T-score between -2.5 and -4.0 at the lumbar spine or total hip. Denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26 to 0.41; P<0.001) and hip fractures by 40% (relative risk 0.60, 95% CI 0.37 to 0.97; P=0.04) compared with placebo at 36 months. FREEDOM trial, NEJM 2009 Because those results led directly to FDA approval, any patient meeting the label's criteria has a regulatory right to the drug through commercial channels, not through an experimental access pathway.

Amgen SupportPlus: The Primary Free-Drug Pathway for Uninsured Patients

For patients with no insurance or inadequate coverage, Amgen's SupportPlus program is the most direct route to free Prolia injections. The program provides the medication at no cost to eligible patients, and enrollment is handled by phone or online.

Eligibility Criteria in 2026

Amgen sets income thresholds as a percentage of the Federal Poverty Level (FPL). As of the most recent program update, patients with household income at or below 500% of FPL who lack coverage for Prolia may qualify for free medication. For a single-person household in 2026, 500% FPL is approximately $76,300 per year. Patients with Medicare Part D who are in the coverage gap or who face high deductibles may also be eligible under a separate low-income tier.

Eligibility requirements include:

• U.S. Residency
• A valid Prolia prescription from a licensed U.S. Prescriber
• Household income documentation (tax return, pay stubs, or attestation)
• Proof of insurance status (or attestation of no coverage)

Enrollment: call 1-888-4PROLIA (1-888-477-6542) or visit Amgen's patient support portal. The program ships directly to the prescribing physician's office, not to the patient's home, because Prolia requires refrigeration and in-office subcutaneous administration.

How Long Free Drug Lasts

The program typically provides medication for 12 months, with annual re-enrollment. Patients whose financial situation changes mid-year should contact SupportPlus promptly, because drug shipments are tied to the prescriber's office and require coordination.

Co-Pay Assistance Cards: Reducing Out-of-Pocket Costs for Insured Patients

Patients with commercial (non-government) insurance can use Amgen's co-pay assistance card to reduce their share of the injection cost. The card functions like a secondary payer and covers a portion of the co-pay or co-insurance amount after the primary insurer processes the claim.

How the Amgen Co-Pay Card Works

Amgen's co-pay program for Prolia has historically covered up to $1,200 per year in patient out-of-pocket costs. The card is activated online or by phone and is presented at the physician's office at the time of each injection. Because Prolia is administered in a clinical setting rather than picked up at a retail pharmacy, the billing goes through the office or outpatient facility.

Patients with Medicare, Medicaid, TRICARE, or any other federal or state government insurance are not eligible for manufacturer co-pay cards under the federal anti-kickback framework. OIG guidance on pharmaceutical manufacturer patient assistance programs

Independent Co-Pay Foundations

For patients on government insurance, independent nonprofit organizations fill the gap that manufacturer programs cannot. The following foundations have accepted applications for osteoporosis drugs in recent years:

• HealthWell Foundation (healthwellfoundation.org): osteoporosis fund opened for enrollment periodically.
• Patient Advocate Foundation Co-Pay Relief (copays.org): income-based grants for qualifying diagnoses.
• Bone Health and Osteoporosis Foundation (bonesource.org): maintains a financial assistance resource directory.

Grant amounts and fund availability change quarterly. Patients should apply early in the calendar year, as many foundations exhaust funds by mid-year.

The 340B Drug Pricing Program: Lower Costs at Qualifying Clinics

The 340B program, established under Section 340B of the Public Health Service Act, requires drug manufacturers to sell outpatient drugs at a statutory ceiling price to covered entities. For Prolia, 340B pricing can reduce acquisition cost by 25% to 50% or more compared with the wholesale acquisition cost.

Which Facilities Qualify

Covered entities include:

• Federally Qualified Health Centers (FQHCs) and FQHC Look-Alikes
• Ryan White HIV/AIDS clinics
• Disproportionate Share Hospital (DSH) outpatient departments
• Children's hospitals and critical access hospitals meeting DSH thresholds

Patients do not need to meet income criteria to receive 340B-priced drugs at a covered entity. The savings accrue to the facility, which may pass them on as reduced charges, sliding-scale fees, or charity care. To find a 340B-covered facility near you, use the HRSA 340B database at hrsa.gov/opa/eligibility-and-registration/covered-entities.

340B and Medicare Part B Billing

Prolia is typically billed under Medicare Part B as a physician-administered drug (HCPCS code J0897). Under 340B, a covered entity acquires the drug at the 340B ceiling price but may bill Medicare at the average sales price (ASP) plus 6%. For the patient, the cost-sharing obligation under Part B is 20% of the Medicare-approved amount after the Part B deductible. Patients enrolled in a Medicare Supplement (Medigap) plan may have that 20% covered by their supplemental policy. CMS Medicare Part B drug coverage overview

Medicare Part D and Part B Coverage for Prolia

Prolia's coverage pathway under Medicare depends on the setting in which it is administered.

Part B Coverage

Because Prolia is a self-administered subcutaneous injection that requires clinical supervision and refrigeration, Medicare generally covers it under Part B when administered in a physician's office or outpatient hospital. The 2024 Medicare average sales price for denosumab 60 mg/mL was approximately $1,062 per injection, with beneficiary cost-sharing of roughly $212 before Medigap. CMS ASP pricing files

Part D Coverage

Some Part D plans cover Prolia when a patient self-administers or obtains it through a specialty pharmacy arrangement. Coverage and tier placement vary by plan. Patients should check their plan's formulary during the annual enrollment period (October 15 to December 7) using Medicare's Plan Finder tool at medicare.gov.

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug spending at $2,000 starting in 2025, which meaningfully reduces catastrophic-phase exposure for patients taking high-cost biologics like Prolia. IRA Medicare drug pricing provisions, CMS

HSA and FSA Eligibility for Prolia

Yes, Prolia is HSA and FSA eligible. As an FDA-approved prescription drug administered by a licensed prescriber, denosumab qualifies as a medical expense under IRS Publication 502.

Practical HSA/FSA Use

Patients with commercial insurance who use an Amgen co-pay card first and then apply remaining out-of-pocket costs against an HSA or FSA can stack both benefits, as long as the HSA/FSA reimburses only amounts not covered by any other assistance. Using HSA/FSA dollars effectively converts the cost to pre-tax spending, reducing the real after-tax burden by 22% to 37% depending on the patient's federal marginal tax bracket.

For patients on high-deductible health plans who receive Prolia twice yearly, the two injections may together exhaust a significant portion of the deductible. Timing the first injection early in the year can accelerate deductible satisfaction and reduce cost-sharing on other services for the rest of the year. IRS Publication 502, Medical and Dental Expenses

Biosimilar Denosumab: The Emerging Lower-Cost Option

The FDA approved two denosumab biosimilars in 2024: denosumab-bddz (brand name Jubbonti, for osteoporosis indications) and denosumab-pbgh (brand name Wyost, for oncology indications including giant cell tumor of bone), both from Sandoz. A third biosimilar, denosumab-bnht (Osenvelt, from Fresenius Kabi), also received FDA approval in 2024.

What Biosimilar Approval Means for Cost

FDA biosimilar approval requires demonstration of no clinically meaningful differences in safety, purity, and potency compared with the reference product (Prolia). The FDA's 2024 approval letters for Jubbonti confirmed interchangeability with Prolia at the pharmacy level for applicable states. FDA biosimilar approval for Jubbonti

Biosimilar entry historically reduces net prices by 20% to 40% within 2 years of launch, based on patterns seen with other biologic drug classes. Patients and prescribers should ask their insurer whether a biosimilar denosumab is on a preferred tier, as switching to a biosimilar may lower co-insurance substantially without any change in clinical effect.

Negotiating and Comparing Prices: GoodRx, Cost-Plus Drugs, and Specialty Pharmacies

For the minority of patients who pay cash, price comparison tools can identify meaningful savings, though Prolia's distribution is largely limited to specialty and physician-office channels.

GoodRx and Similar Discount Cards

GoodRx and similar discount platforms list cash prices for Prolia, but because the drug is a physician-administered biologic, the discount applies at specialty pharmacies that ship to prescribing offices. As of early 2026, GoodRx cash prices for one Prolia prefilled syringe (60 mg/mL) range from approximately $950 to $1,350 depending on pharmacy. GoodRx discounts cannot be combined with insurance billing on the same claim.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists generic small-molecule drugs at cost-plus-15% margins, but biologics like Prolia are not currently in their formulary because of the cold-chain logistics and specialty distribution requirements.

HealthRX Access Decision Framework for Prolia Cost Reduction

Use the following decision tree to identify the highest-priority pathway for each patient:

1. No insurance, income at or below 500% FPL. Apply to Amgen SupportPlus for free drug first.
2. Commercial insurance with high co-pay. Activate Amgen co-pay card; stack with HSA/FSA for remaining balance.
3. Medicare Part B with no Medigap. Seek a 340B-covered facility for administration; apply to HealthWell Foundation if income-eligible.
4. Medicare Part D or Medicaid. Co-pay cards are not permitted; apply to Patient Advocate Foundation Co-Pay Relief or HealthWell Foundation.
5. Any insurance, biosimilar now on formulary. Ask prescriber to switch to interchangeable denosumab biosimilar to access lower tier co-pay.
6. Off-label unapproved indication (e.g., pediatric giant cell tumor). Physician files FDA Form 3926 for individual expanded access IND; contact Amgen Medical Affairs at medinfo@amgen.com.

Prior Authorization and Step Therapy: Removing Insurance Barriers

Many commercial and Medicare Advantage plans require prior authorization (PA) before covering Prolia. Typical PA criteria include a documented dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5, or a prior low-trauma fracture in a patient with osteopenia (T-score between -1.0 and -2.5).

Step Therapy Requirements

Some plans require a trial of an oral bisphosphonate (most commonly alendronate 70 mg weekly) before approving Prolia. The American Society for Bone and Mineral Research (ASBMR) clinical practice guidance notes that step therapy is inappropriate for patients with documented bisphosphonate intolerance, esophageal disease, inability to remain upright for 30 minutes, or renal impairment with creatinine clearance below 35 mL/min. ASBMR clinical practice guide on osteoporosis pharmacotherapy, JBMR 2022

Appealing a Denial

If a PA request is denied, the prescriber should file a peer-to-peer review request within 5 business days. Attach the DXA report, fracture history, and any documentation of bisphosphonate contraindication. If the peer-to-peer review is also denied, file a formal grievance and request an expedited external review under the ACA's external appeal provisions. State insurance commissioners can be contacted if internal appeals are exhausted.

Discontinuation Risk: Why Continuous Access Matters Clinically

Patients who stop Prolia injections without transitioning to a bisphosphonate face a measurable rebound fracture risk. A 2017 case series and subsequent analyses documented that vertebral fractures can occur within 12 to 18 months of the last injection, with some patients experiencing multiple simultaneous fractures. The rate of vertebral fracture after Prolia discontinuation in one analysis was approximately 7.1 per 100 patient-years, compared with approximately 1.2 per 100 patient-years in patients who continued therapy. Cummings et al., Osteoporosis International, 2018

This clinical reality makes uninterrupted access a safety issue, not merely a convenience issue. Prescribers should begin exploring patient assistance options at least 90 days before a scheduled injection to allow time for enrollment, approval, and drug shipment.

Practical Steps to Take Before Your Next Prolia Injection

Getting organized early is the single most reliable way to avoid a gap in therapy. Below is a concrete action checklist.

• Confirm insurance coverage and current tier status at least 90 days before the injection date.
• If uninsured or income-eligible, submit the Amgen SupportPlus application with income documentation before the appointment is scheduled.
• If commercially insured, download and activate the Amgen co-pay card at amgensupportplus.com before the visit.
• Ask the prescribing office whether they are a 340B-covered entity; if not, ask for a referral to one if cost is a barrier.
• Check whether a denosumab biosimilar (Jubbonti or Osenvelt) is on a preferred formulary tier with your insurer; ask the prescriber if switching is clinically appropriate for you.
• Confirm that your HSA/FSA administrator recognizes physician-administered biologics for reimbursement (most do, but some restricted-purpose FSA plans exclude them).
• If you have Medicare Part D, review your plan's formulary annually during the October 15 to December 7 enrollment window.